Review



tle1 antigen  (Boster Bio)


Bioz Verified Symbol Boster Bio is a verified supplier
Bioz Manufacturer Symbol Boster Bio manufactures this product  
  • Logo
  • About
  • News
  • Press Release
  • Team
  • Advisors
  • Partners
  • Contact
  • Bioz Stars
  • Bioz vStars
    • 93
      Buy from Supplier

    Structured Review

    Boster Bio tle1 antigen
    FIGURE 5 The expression of FHL1, BCL2, <t>TLE1,</t> KIT, PPARGC1A and GHR in papillary thyroid carcinoma (PTC) and the control group. FHL1 showed strong positivity in the nuclei and to a lesser extent in the cytoplasm of normal thyroid tissues adjacent to the tumour (the control group), but is not present in the PTC tissues. (p < 0.01). There was no significant difference in the expression of BCL2 between PTC and normal thyroid tissues (p > 0.05). The results showed that TLE1, KIT, PPARGC1A, and GHR were absent in both tumor and normal tissues. (magnification ×200). FHL1, four and a half LIM domains 1.
    Tle1 Antigen, supplied by Boster Bio, used in various techniques. Bioz Stars score: 93/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
    https://www.bioz.com/result/tle1 antigen/product/Boster Bio
    Average 93 stars, based on 1 article reviews
    tle1 antigen - by Bioz Stars, 2026-04
    93/100 stars

    Images

    1) Product Images from "FHL1: A novel diagnostic marker for papillary thyroid carcinoma."

    Article Title: FHL1: A novel diagnostic marker for papillary thyroid carcinoma.

    Journal: Pathology international

    doi: 10.1111/pin.13467

    FIGURE 5 The expression of FHL1, BCL2, TLE1, KIT, PPARGC1A and GHR in papillary thyroid carcinoma (PTC) and the control group. FHL1 showed strong positivity in the nuclei and to a lesser extent in the cytoplasm of normal thyroid tissues adjacent to the tumour (the control group), but is not present in the PTC tissues. (p < 0.01). There was no significant difference in the expression of BCL2 between PTC and normal thyroid tissues (p > 0.05). The results showed that TLE1, KIT, PPARGC1A, and GHR were absent in both tumor and normal tissues. (magnification ×200). FHL1, four and a half LIM domains 1.
    Figure Legend Snippet: FIGURE 5 The expression of FHL1, BCL2, TLE1, KIT, PPARGC1A and GHR in papillary thyroid carcinoma (PTC) and the control group. FHL1 showed strong positivity in the nuclei and to a lesser extent in the cytoplasm of normal thyroid tissues adjacent to the tumour (the control group), but is not present in the PTC tissues. (p < 0.01). There was no significant difference in the expression of BCL2 between PTC and normal thyroid tissues (p > 0.05). The results showed that TLE1, KIT, PPARGC1A, and GHR were absent in both tumor and normal tissues. (magnification ×200). FHL1, four and a half LIM domains 1.

    Techniques Used: Expressing, Control



    Similar Products

    tle1 antigen  (Boster Bio)
    93
    Boster Bio tle1 antigen
    FIGURE 5 The expression of FHL1, BCL2, <t>TLE1,</t> KIT, PPARGC1A and GHR in papillary thyroid carcinoma (PTC) and the control group. FHL1 showed strong positivity in the nuclei and to a lesser extent in the cytoplasm of normal thyroid tissues adjacent to the tumour (the control group), but is not present in the PTC tissues. (p < 0.01). There was no significant difference in the expression of BCL2 between PTC and normal thyroid tissues (p > 0.05). The results showed that TLE1, KIT, PPARGC1A, and GHR were absent in both tumor and normal tissues. (magnification ×200). FHL1, four and a half LIM domains 1.
    Tle1 Antigen, supplied by Boster Bio, used in various techniques. Bioz Stars score: 93/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
    https://www.bioz.com/result/tle1 antigen/product/Boster Bio
    Average 93 stars, based on 1 article reviews
    tle1 antigen - by Bioz Stars, 2026-04
    93/100 stars
    		  Buy from Supplier

    Image Search Results


    FIGURE 5 The expression of FHL1, BCL2, TLE1, KIT, PPARGC1A and GHR in papillary thyroid carcinoma (PTC) and the control group. FHL1 showed strong positivity in the nuclei and to a lesser extent in the cytoplasm of normal thyroid tissues adjacent to the tumour (the control group), but is not present in the PTC tissues. (p < 0.01). There was no significant difference in the expression of BCL2 between PTC and normal thyroid tissues (p > 0.05). The results showed that TLE1, KIT, PPARGC1A, and GHR were absent in both tumor and normal tissues. (magnification ×200). FHL1, four and a half LIM domains 1.

    Journal: Pathology international

    Article Title: FHL1: A novel diagnostic marker for papillary thyroid carcinoma.

    doi: 10.1111/pin.13467

    Figure Lengend Snippet: FIGURE 5 The expression of FHL1, BCL2, TLE1, KIT, PPARGC1A and GHR in papillary thyroid carcinoma (PTC) and the control group. FHL1 showed strong positivity in the nuclei and to a lesser extent in the cytoplasm of normal thyroid tissues adjacent to the tumour (the control group), but is not present in the PTC tissues. (p < 0.01). There was no significant difference in the expression of BCL2 between PTC and normal thyroid tissues (p > 0.05). The results showed that TLE1, KIT, PPARGC1A, and GHR were absent in both tumor and normal tissues. (magnification ×200). FHL1, four and a half LIM domains 1.

    Article Snippet: Slides were immunostained with monoclonal antibodies against the BCL2 antigen (clone SP66, Maixin), CD117/C‐kit antigen (clone YR145, Maixin), and with monoclonal antibodies against the FHL1 (10991‐1‐AP, Proteintech Group, Inc.), PPARGC1A (Boster, China), and TLE1 antigen (Maixin).

    Techniques: Expressing, Control